Given months to live, he decided to volunteer in every state
With about 12 to 18 months to live, Ruch, 55, considered helping Hurricane Helene victims in North Carolina or wildfire victims in the Los Angeles area. But that wasn't enough, he said, because he wanted to reach residents in all 50 states and D.C.
Subscribe to The Post Most newsletter for the most important and interesting stories from The Washington Post.
He had spent most of his savings on his cancer treatment, so he decided he would launch a fundraiser and hope others would help him achieve his dying wish: volunteering in every state.
Ruch received enough money to start his journey, so he packed all his belongings into his 2017 Chevrolet Malibu last month and headed north. He has since volunteered at food pantries, food banks, soup kitchens, senior centers, hospitality houses and other charity organizations in almost a dozen states and is now driving southeast from Seattle.
He said he hopes to raise at least $42,000 and reach every state by the fall. Getting attention for it is slightly uncomfortable, he said.
'I don't want to be some pseudo celebrity, because I'm not,' Ruch told The Washington Post. 'I'm just a guy that needed to balance the scales and do some good in his life.'
A terminal diagnosis, he said, can put life into perspective quickly. But his volunteering is not all selfless. Studies have shown that people who volunteer get a boost of self-esteem, feel more connected to other people and experience less depression.
Ruch, who had not volunteered much before this year, said he has been battling prostate cancer since May 2021 and twice underwent external beam radiation therapy, spending about $80,000 on treatment. In late January, Ruch said scans showed his cancer, now Stage 4, had spread to his liver and a bone in his right leg.
He said his doctor presented him with two options: Undergo chemotherapy and possibly live for about two years, or eschew treatment and die within about 18 months.
For the following few days, Ruch, who's single, reflected on his life: what he felt he did right and wrong, what he could've done better and what he felt he should've spent more time doing - or less time doing, such as working.
He wanted to try to improve other people's lives in every state, he said, so he decided against continuing treatment and quit his job in the rooftop solar industry.
He jotted down his thoughts in a notebook to form a plan. He asked himself what he was doing. 'Serving,' he wrote. Then he asked himself why he was doing it. 'Dying,' he wrote.
That's when Ruch's idea came together. He could start a project called Dying to Serve - he solidified the name after seeing an available domain name for the phrase on GoDaddy - and hope others would support him. He identified an efficient cross-country driving route on Google Maps.
He started a GoFundMe in February that he shared on social media.
'Anything you can spare would be greatly appreciated and used to fund my travel, housing, volunteer efforts and medical necessities to keep me going as long as possible,' he wrote.
He added that he spent his life savings fighting his cancer 'due to the broken United States health care system.'
As his fundraiser spread on social media and raised thousands of dollars, Ruch created a graphic detailing his mock schedule, which looked similar to a sports team's schedule announcement. He signed up for shifts through JustServe, VolunteerMatch and other organizations that share volunteering opportunities.
He moved out of his apartment last month and stuffed his red Malibu, which he nicknamed the Flash, with his belongings - clothes, three suitcases, two backpacks, his laptop, blankets, pillows, a massage gun to soothe his leg pains, energy drinks made with adaptogens and even a printer, in case he needed it.
His first stop was a Dallas food pantry on March 17, when he sorted, packaged and distributed food. From there, he went to Norman, Oklahoma; Wichita; Pueblo, Colorado; Santa Fe, New Mexico; Phoenix; Las Vegas; Southern and Northern California; Lake Oswego, Oregon; and Seattle. He'll visit Meridian, Idaho, and Salt Lake City this week.
Ruch has driven more than 4,000 miles, he said, but his cancer forces him to stop to relieve himself about every hour. He has been sleeping at hotels and Airbnbs, keeping each stay around $100.
He was exhausted after initially scheduling volunteer shifts every day or so, and he's now trying to complete one shift roughly every three days. He's taking longer, scenic driving routes, and he's scheduling other activities he enjoys - like attending a Seattle Mariners home game Wednesday.
Regardless of his schedule, Ruch said he wakes up on days he volunteers 'so happy' and feels like he was 'shot out of a cannon.' His shifts are usually between two and four hours long.
Still, Ruch said he sometimes has doubts about his project on days he doesn't volunteer, wondering whether he'll stay healthy, whether he'll raise enough money and whether his car will keep functioning.
He has accepted help along the way, receiving discounts at hotels, Airbnbs, restaurants and car maintenance shops after sharing his story. A man in Fresno, California, who saw Ruch's online fundraiser bought him lunch and gave him $100, Ruch said. Ruch has raised more than $24,000.
As Ruch's project has received more publicity in the past few weeks, a handful of people have volunteered alongside him. He has had notoriety at some organizations where he volunteers, he said, but he tries to deflect the attention.
Ruch plans his travels a few weeks in advance, and he said he might reach the East Coast around June. He said he'll fly to Alaska and Hawaii.
'I need to finish this,' Ruch said.
If he's healthy after visiting every state, he said he'll keep volunteering. Ruch hopes his project will spark a volunteer movement that'll continue after he dies.
'If I can inspire hundreds or thousands of people nationwide to volunteer, even if it's three or four hours a month,' Ruch said, 'then I can die happy.'
Related Content
Ja Morant dares the NBA to punish him, knowing it won't pull the trigger
Scientists are 'X-raying' the Amazon, unlocking a lost human history
The Smithsonian could be the beginning of Trump's plan to edit history. Or the end.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Hill
6 hours ago
- The Hill
NIH director offers reason for cutting vaccine contracts
Bhattacharya said in a recent episode of the podcast 'War Room' and then again in an opinion piece in The Washington Post, the Department of Health and Human Services (HHS) chose to cancel millions of dollars in mRNA contracts because the American public does not trust the technology. His reasoning differs from the explanation HHS Secretary Kennedy gave for canceling $500 million worth of mRNA contracts last week. Kennedy justified the move by claiming the technology does not meet 'current scientific standards.' Bhattacharya called mRNA a promising technology that could lead to better treatments for diseases like cancer. But he expressed concern over just how much antigen mRNA vaccines produce and leave in the body, even though other types of vaccines share the same issue and are considered safe and effective. Bhattacharya blamed public distrust in mRNA on vaccine mandates and other public health safety measures issued under the Biden administration, arguing that his administration did not properly address concerns about the vaccine's safety and efficacy. 'As a vaccine intended for broad public use, especially during a public health emergency, the platform has failed a crucial test: earning public trust,' he wrote. 'No matter how elegant the science, a platform that lacks credibility among the people it seeks to protect cannot fulfill its public health mission.' outspoken critic of lockdown measures and vaccine mandates.
The Hill
7 hours ago
- The Hill
NIH cancels mRNA vaccine contracts, citing lack of public trust
National Institutes of Health Director Jay Bhattacharya claims the federal government recently cancelled millions of dollars' worth of mRNA research contracts because the general public does not trust the technology. Bhattacharya explained the reason behind the abrupt contract cancellations, first, during an episode of Republican political strategist Steve Bannon's podcast 'War Room' last week and again in an opinion piece recently published in The Washington Post. In the article, Bhattacharya called the mRNA platform a 'promising technology' and acknowledged that it may lead to breakthroughs in treatment for diseases like cancer. 'But as a vaccine intended for broad public use, especially during a public health emergency, the platform has failed a crucial test: earning public trust,' he wrote. 'No matter how elegant the science, a platform that lacks credibility among the people it seeks to protect cannot fulfill its public health mission.' Bhattacharya's explanation for the administration's pivot away from mRNA technology differs from that of his boss, Health and Human Services Secretary Robert F. Kennedy Jr. Kennedy announced last week the agency would wind down its mRNA vaccine development activities under the Biomedical Advanced Research and Development Authority (BARDA) and cancel $500 million worth of contracts related to the technology. He said that mRNA technologies funded during the pandemic failed to meet current scientific standards and that the federal government would shift its focus to whole-virus vaccines and novel platforms. Bhattacharya expressed concern in the article about mRNA vaccines' ability to direct human cells to produce spike proteins to trigger an immune response. He argues the scientific community does not have a clear understanding of where mRNA product stays in the body, for how long, and whether other proteins are created in the process. Scott Hensley, a microbiology professor at the University of Pennsylvania's Perelman School of Medicine, told STAT that these are also issues with vaccines that use live but weakened viruses like the measles, mumps, and rubella vaccine, which federal health agencies have deemed safe and effective. 'This is why we complete human clinical studies before vaccines are widely used in humans,' he told the outlet. 'The mRNA and live attenuated vaccine platforms have both proven to be safe and effective in clinical trials.' He blamed public distrust in mRNA on the Biden administration's COVID-19 vaccine mandates during the pandemic. Bhattacharya expressed concern in the article about mRNA vaccines' ability to direct human cells to produce spike proteins to trigger an immune response. He argues the scientific community does not have a clear understanding of where the mRNA product stays in the body, for how long, and whether other proteins are created in the process. 'Science isn't propaganda,' he wrote. 'It's humility. And when public health officials stopped communicating with humility, we lost much of the public, an absolute necessity for any vaccine platform.'
NBC News
20 hours ago
- NBC News
Medicare Part D premiums are likely to go up next year. Here's why.
Medicare enrollees who buy the optional Part D drug benefit may see substantial premium price hikes — potentially up to $50 a month — when they shop for next year's coverage. Such drug plans are used by millions of people who enroll in what is called original Medicare, the classic federal government program that began in 1965 and added a drug benefit only in 2006. The drug plans are offered through private insurers, and enrollees must pay monthly premiums. It's not known whether insurers will pursue the maximum increase allowed, as premium prices for next year won't be revealed until closer to open enrollment, which starts Oct. 15. Increases are expected to mainly affect stand-alone Part D plans, not the drug coverage offered as part of Medicare Advantage, the private sector alternative to original Medicare. More on that later. Policy experts say premiums are likely to go up for several reasons, including increased use of some higher-cost prescription drugs; a law that capped out-of-pocket spending for enrollees; and changes in a program aimed at stabilizing price increases that the Trump administration has continued but made less generous. One thing is surer than ever, say many policy experts: Beneficiaries should not simply roll over their existing stand-alone Medicare drug plans. 'Everyone should shop plans in open enrollment,' said Stacie Dusetzina, a professor of health policy at Vanderbilt University Medical Center. Here are three reasons prices would rise. 1. It's the spending! Every year, insurers keep an eye on what they're spending on drugs so they can build that into their premium estimates. Spending covers both the prices charged by drugmakers and volume, meaning how many people take the medications and how often. And it's up. Spending by insurers and government programs for prescription drugs in 2024 across the market grew more than 10%, which is slightly greater than in recent years, according to a research report published last month in the American Journal of Health-System Pharmacy. Estimates are not yet available for this year's trends. Still, in 2024, researchers found that drug prices overall decreased slightly. Spending rose because of drugs coming on the market and increased utilization, especially for pricey weight loss drugs and another category of medications that treat various autoimmune conditions, such as rheumatoid arthritis. Such increased use is evident in Medicare. Many beneficiaries, for example, are treated for autoimmune conditions. And even though Medicare doesn't cover treatment for weight loss, many members have diabetes or other conditions that the new weight loss drugs can treat. The Trump administration, according to The Washington Post, is considering a five-year pilot program in which Medicare Part D plans could voluntarily expand access to the drugs, which can cost more than $1,000 a month without insurance. Details have not yet been provided, but the pilot program would not begin in Medicare until 2027. Another wild card for insurers is the Trump administration's tariffs on businesses that purchase products made overseas, which could boost drug prices because the U.S. imports a lot of its pharmaceuticals. Much, however, remains unknown about whether drugmakers will pass along any additional tariff costs to consumers. So, while rising spending is one factor, it isn't the only reason next year's premium prices are expected to go up. 2. New out-of-pocket caps for consumers Changes made to Medicare aimed at helping people with high out-of-pocket costs for expensive medications may be a bigger factor. Here's why: Starting this year, Medicare enrollees have a limit on how much they must pay out-of-pocket for prescription drugs. It's capped at $2,000, a threshold that will rise each year to cover inflation. Lawmakers in Congress set those changes in the Inflation Reduction Act under President Joe Biden. The law also shifted a larger share of the cost of drugs used by Medicare beneficiaries from the federal program to insurers. That $2,000 cap is a big change from previous years, when people taking expensive drugs had a higher threshold to meet annually and were on the hook to pay 5% of the drug's cost even after meeting that amount. Those additional 5% payments ended last year under the provisions of the IRA. Before that law passed, 'people would spend $10,000 or $15,000 out-of-pocket each year just for a single drug,' Dusetzina said. 'The Inflation Reduction Act was necessary to make Part D proper health insurance, but there's a cost to do so.' While the cap is a big help for affected consumers, the reduced amounts paid by some beneficiaries — coupled with the cost shift to insurers — could lead plans to spread their increased expenses across all policyholders through higher premiums. A growing number of health plans have also begun to require enrollees to pay a percentage of a drug's cost, rather than a flat-dollar copay, which can lead to larger-than-expected costs at the pharmacy counter, Dusetzina said. While consumers not currently taking high-cost specialty drugs may not see a benefit in the $2,000 cap initially, they might one day, say policy experts, who note that drugmaker prices continue to rise and that enrollees could fall ill with a condition like cancer or multiple sclerosis for which they need a very high-priced drug. 'It's important to think not just in context of those groups who hit the cap every year, but also people are paying more in premiums to protect their future selves as well,' said Casey Schwarz, the senior counsel for education and federal policy at the Medicare Rights Center, an advocacy group. The new prescription drug cap and other changes apply to both the stand-alone Part D drug plans and Medicare Advantage plans. But those Medicare Advantage plans are not expected to increase the drug portion of their premiums, partly because the private sector plans are paid more per member than what it costs taxpayers for the traditional program. That means Advantage plans have far more money to add benefits, such as vision and dental coverage, which traditional Medicare does not include, or to use them to cushion the impact of rising spending on drug costs, thus limiting premium increases. Those additional benefits are advertised to attract customers to Medicare Advantage, which also sometimes offers plans with minimal or no monthly premium costs. There are other differences between traditional Medicare and private sector plans. For example, Advantage members must stick to doctors and hospitals in the plan's networks, and they may face more prior authorization or other hurdles than in the traditional program. The growing difference between premiums — fueled by the extra rebates flowing to the private sector plans — 'is increasingly tilting coverage toward Medicare Advantage and making traditional Medicare plus a stand-alone PDP [prescription drug plan] unaffordable for many enrollees,' said Juliette Cubanski, deputy director of the program on Medicare policy at KFF, a health information nonprofit that includes KFF Health News. 3. Trump administration reduced funding meant to slow premium growth The final factor in the premium increase equation is a program set up to slow the rise of premiums in stand-alone Part D plans. It began under the Biden administration to offset premium increases tied to changes in the Inflation Reduction Act by temporarily injecting additional federal dollars to help insurers adjust to the new rules. That plan sent just over $6 billion this year to Part D insurers. And it had an effect. The average monthly premium for a stand-alone Part D drug plan dropped 9%, from $43 last year to $39 this year, according to KFF, even when factoring in that some plans raised prices by up to $35 a month, the maximum increase allowed under the stabilization plan for this year. In a memo released in late July, the Trump administration said it would continue the program for next year, while shaving about 40% of the funding. A government official told The Wall Street Journal that the administration felt that keeping the full funding would have mainly benefited the insurers and cost taxpayers an 'enormous, excess amount.' The stabilization effort next year will send $10 a month per enrollee to Part D insurers to help keep premiums in check, down from $15 this year. Among other changes, it allows insurers to raise premiums by as much as $50 a month, up from the $35 allowed this year. That would be a substantial increase, Cubanski noted, although it is not clear just how many insurers would pursue the full amount. 'We did see some plans this year were taking premium increases of that $35 amount in 2025, and I fully expect we will see some plans with increases up to $50 a month' next year, she said. Another reason to take a close look at all the options once open enrollment begins.
